Tandem Diabetes Care TNDM Amortization expense related to capitalized debt issuance costs
Amortization expense related to capitalized debt issuance costs at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tandem Diabetes Care's amortization expense related to capitalized debt issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tandem Diabetes Care's amortization expense related to capitalized debt issuance costs?
- Tandem Diabetes Care (TNDM) reported amortization expense related to capitalized debt issuance costs of $576K in Q1 2026.
- How has Tandem Diabetes Care's amortization expense related to capitalized debt issuance costs changed year-over-year?
- Tandem Diabetes Care's amortization expense related to capitalized debt issuance costs increased by 14.1% year-over-year, from $505K to $576K.
- What is the long-term trend for Tandem Diabetes Care's amortization expense related to capitalized debt issuance costs?
- Over 3 years (2022 to 2025), Tandem Diabetes Care's amortization expense related to capitalized debt issuance costs has grown at a -0.6% compound annual growth rate (CAGR), from $1.9M to $1.86M.